Comparative Pharmacology
Head-to-head clinical analysis: AURLUMYN versus KADCYLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AURLUMYN versus KADCYLA.
AURLUMYN vs KADCYLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
KADCYLA (ado-trastuzumab emtansine) is an antibody-drug conjugate composed of trastuzumab, a humanized anti-HER2 antibody, linked to the microtubule inhibitor DM1 (maytansinoid). It binds to HER2 receptors on tumor cells, internalized via receptor-mediated endocytosis, and releases DM1 intracellularly, causing cell cycle arrest and apoptosis.
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
3.6 mg/kg intravenously every 3 weeks until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (CrCl <30 mL/min).
Terminal half-life approximately 4 days (range 2.8-5.6 days), supporting every-3-week dosing.
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Primarily hepatic metabolism with biliary excretion; minimal renal elimination (<10% unchanged).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent